News & Updates
Showing Multidisciplinary articles
Showing
Show Multimedia Only

96-week PULSAR data support aflibercept 8 mg for nAMD
29 May 2026
byAudrey Abella
Updated results from the phase III PULSAR trial show that intravitreal (IVT) aflibercept 8 mg, when administered at extended dosing intervals of up to 20 weeks, led to visual gains and anatomic improvements comparable to the 2-mg dose, with no new safety concerns over 96 weeks, in treatment-naïve individuals with neovascular age-related macular degeneration (nAMD).
96-week PULSAR data support aflibercept 8 mg for nAMD
29 May 2026
Low, high BMI tied to impairments in daily activities
28 May 2026
byStephen Padilla
Individuals with overweight or obesity, as well as those who are underweight, are predisposed to limitations in activities of daily living (ADL), reveals a study.







